Advances and challenges in management of invasive mycoses

Lancet

Volumn 366, Issue 9490, 2005, Pages 1013-1025

  Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAPAMYCIN; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANOREXIA; ANTIBIOTIC SENSITIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG COST; DRUG TOLERABILITY; FEVER; FUNGAL VIRULENCE; FUNGUS IDENTIFICATION; FUSARIUM; GASTROINTESTINAL TOXICITY; HOSPITAL INFECTION; HUMAN; HYALOHYPHOMYCOSIS; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TOXICITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; PHAEOHYPHOMYCOSIS; PRIORITY JOURNAL; RADIODIAGNOSIS; RASH; RISK ASSESSMENT; SALVAGE THERAPY; SCEDOSPORIUM APIOSPERMUM; SKIN TOXICITY; VISUAL DISORDER; VOMITING;

EID: 24944438172     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67381-3     Document Type: Conference Paper

References (183)

1. TF Patterson, WR Kirkpatrick, M White Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes Medicine (Baltimore) 79 2000 250 260
2. SJ Lin, J Schranz, SM Teutsch Aspergillosis case-fatality rate: systematic review of the literature Clin Infect Dis 32 2001 358 366
3. PG Pappas, JH Rex, J Lee A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients Clin Infect Dis 37 2003 634 643
4. KA Marr, RA Carter, F Crippa, A Wald, L Corey Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients Clin Infect Dis 34 2002 909 917
5. MM McNeil, SL Nash, RA Hajjeh Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997 Clin Infect Dis 33 2001 641 647
6. AH Groll, PM Shah, C Mentzel, M Schneider, G Just-Nuebling, K Huebner Trends in the postmortem epidemiology of invasive fungal infections at a university hospital J Infect 33 1996 23 32
7. KA Marr, K Seidel, TC White, RA Bowden Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole J Infect Dis 181 2000 309 316
8. O Gudlaugsson, S Gillespie, K Lee Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 2003 1172 1177
9. AM Tortorano, E Biraghi, A Astolfi European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region J Hosp Infect 51 2002 297 304
10. A Viudes, J Peman, E Canton, P Ubeda, JL Lopez-Ribot, M Gobernado Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death Eur J Clin Microbiol Infect Dis 21 2002 767 774
11. L Ostrosky-Zeichner New approaches to the risk of Candida in the intensive care unit Curr Opin Infect Dis 16 2003 533 537
12. G Ramage, BL Wickes, JL Lopez-Ribot Biofilms of Candida albicans and their associated resistance to antifungal agents Am Clin Lab 20 2001 42 44
13. GS Martin, DM Mannino, S Eaton, M Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
14. J Mora-Duarte, R Betts, C Rotstein Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
15. SB Wey, M Mori, MA Pfaller, RF Woolson, RP Wenzel Hospital acquired candidemia: The attributable mortality and excess length of stay Arch Intern Med 148 1988 2642 2645
16. JE Edwards Jr Invasive Candida infections. Evolution of a fungal pathogen N Engl J Med 324 1991 1060 1062
17. P Eggiman, J Garbino, D Pittet Epidemiology of Candida species infections in critically ill non-immunosuppressed patients Lancet Infect Dis 3 2003 685 702
18. MA Pfaller, RN Jones, SA Messer, MB Edmond, RP Wenzel National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program Diagn Microbiol Infect Dis 30 1998 121 129
19. MA Pfaller, RN Jones, GV Doern, HS Sader, RJ Hollis, SA Messer International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program J Clin Microbiol 36 1998 1886 1889
20. MA Pfaller, DJ Diekema, RN Jones International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program J Clin Microbiol 39 2001 3254 3259
21. MS Rangel-Frausto, T Wiblin, HM Blumberg National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units Clin Infect Dis 29 1999 253 258
22. PG Pappas, JH Rex, JD Sobel Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 189
23. L Ostrosky-Zeichner, JH Rex, PG Pappas Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 2003 3149 3154
24. MA Pfaller, SA Messer, RJ Hollis, RN Jones Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000 Antimicrob Agents Chemother 46 2002 1032 1037
25. MA Pfaller, DJ Diekema, SA Messer, L Boyken, H Huynh, RJ Hollis Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole J Clin Microbiol 40 2002 1694 1697
26. K Bartizal, CJ Gill, GK Abruzzo In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) Antimicrobial Agents Chemother 41 1997 2326 2332
27. TF Patterson Role of newer azoles in surgical patients J Chemotherapy 11 1999 504 512
28. JH Rex, MA Pfaller, JN Galgiani Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections Clin Infect Dis 24 1997 235 247
29. EE Roling, ME Klepser, A Wasson, RE Lewis, EJ Ernst, MA Pfaller Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods Diagn Microbiol Infect Dis 43 2002 13 17
30. DJ Diekema, SA Messer, AB Brueggemann Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study J Clin Microbiol 40 2002 1298 1302
31. MA Pfaller, SA Messer, RJ Hollis, RN Jones, DJ Diekema In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp Antimicrob Agents Chemother 46 2002 1723 1727
32. MA Pfaller, SA Messer, S Coffman In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivatives, LY303366, and other antifungal agents Antimicrob Agents Chemother 41 1997 763 766
33. Villarreal NC, Fothergill AW, Kelly C, Patterson JE, Rinaldi MG, Patterson TF. Candida glabrata resistance to caspofungin during therapy (M-1034). Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct 30-Nov 2, 2004; Washington, DC.
34. D Abi-Said, E Anaissie, O Uzun, I Raad, H Pinzcowski, S Vartivarian The epidemiology of hematogenous candidiasis caused by different Candida species Clin Infect Dis 24 1997 1122 1128
35. C Viscoli, C Girmenia, A Marinus Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) Clin Infect Dis 28 1999 1071 1079
36. DW Denning Early diagnosis of invasive aspergillosis Lancet 355 2000 423 424
37. JR Perfect, GM Cox, JY Lee The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis Clin Infect Dis 33 2001 1824 1833
38. PC Iwen, ME Rupp, AN Langnas, EC Reed, SH Hinrichs Invasive pulmonary aspergillosis due to Aspergillus terreus: 12- year experience and review of the literature Clin Infect Dis 26 1998 1092 1097
39. WJ Steinbach, DK Benjamin Jr, DP Kontoyiannis Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases Clin Infect Dis 39 2004 192 198
40. DA Sutton AW Fothergill MG Rinaldi Guide to clinically significant fungi 1st edn. 1998 Williams and Wilkins Baltimore
41. TJ Walsh, V Petraitis, R Petraitiene Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B J Infect Dis 188 2003 305 319
42. JR Perfect, KA Marr, TJ Walsh Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 2003 1122 1131
43. Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasvie fungal infections (IFI) (abstract M-699). Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct 30-Nov 2, 2004; Washington, DC.
44. A Warris, A Bjorneklett, P Gaustad Invasive pulmonary aspergillosis associated with infliximab therapy N Engl J Med 344 2001 1099 1100
45. FM Marty, SJ Lee, MM Fahey Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study Blood 102 2003 2768 2776
46. TJ Walsh, P Pappas, DJ Winston Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234
47. A Wald, W Leisenring, J-A van Burik, RA Bowden Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation J Infect Dis 175 1997 1459 1466
48. KA Marr, RA Carter, M Boeckh, P Martin, L Corey Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors Blood 100 2002 4358 4366
49. E Jantunen, P Ruutu, L Niskanen Incidence and risk factors for invasive fungal infections in allogenic BMT receipients Bone Marrow Transplant 19 1997 801 808
50. Pappas P. Prospective surveillance for invasive fungal infections (IFIs) in hematopoetic stem cell (HSCTs) and solid organ transplant recipients (SOTs) in the United States (abstract M-1010). 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 14-17, 2003; Chicago, IL: 458.
51. RA Hajjeh, DW Warnock Counterpoint: invasive aspergillosis and the environment - rethinking our approach to prevention Clin Infect Dis 33 2001 1549 1552
52. EJ Anaissie, SL Stratton, MC Dignani Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies Blood 101 2003 2542 2546
53. EJ Anaissie, SF Costa Nosocomial aspergillosis is waterborne Clin Infect Dis 33 2001 1546 1548
54. JR Graybill Aspergillosis: from the breeze or from the bucket? Clin Infect Dis 33 2001 1545
55. A Warris, A Voss, TG Abrahamsen, PE Verweij Contamination of hospital water with Aspergillus fumigatus and other molds Clin Infect Dis 34 2002 1159 1160
56. EJ Anaissie, S Owens, MC Dignani, CK Lee, J Rex, T Walsh Cleaning bathrooms: a novel approach to reducing patient exposure to aerosolized Aspergillus spp Blood 98 2001 207A
57. L Sigler, PR Verweij Aspergillus, Fusarium, and other opportunistic moniliaceous fungi PR Murray EJ Baron JH Jorgensen MA Pfaller RH Yolken Manual of clinical microbiology 8th edn. 2003 American Society for Microbiology Washington, DC 1726 1760
58. DA Sutton Laboratory evaluation of new antifungal agents against rare and refractory mycoses Curr Opin Infect Dis 15 2002 575 582
59. EJ Anaissie, RT Kuchar, JH Rex Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections Clin Infect Dis 33 2001 1871 1878
60. Anaissie E, Kuchar R, Rex JH, Summerbell R, Walsh T. The hospital water system as a reservoir for Fusarium. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997; San Diego, USA.
61. M Nucci, E Anaissie Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management Clin Infect Dis 35 2002 909 920
62. B Castiglioni, DA Sutton, MG Rinaldi, J Fung, S Kusne Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature Medicine (Baltimore) 81 2002 333 348
63. TJ Walsh, I Lutsar, T Driscoll Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children Pediatr Infect Dis J 21 2002 240 248
64. J Guarro, M Nucci, T Akiti Phialemonium fungemia: two documented nosocomial cases J Clin Microbiol 37 1999 2493 2497
65. J Strahilevitz, G Rahav, HJ Schroers An outbreak of Phialemonium infective endocarditis linked to intracavernous penile injections for the treatment of impotence Clin Infect Dis 40 2005 781 786
66. M Nucci, KA Marr, F Queiroz-Telles Fusarium infection in hematopoietic stem cell transplant recipients Clin Infect Dis 38 2004 1237 1242
67. SG Revankar, JE Patterson, DA Sutton, R Pullen, MG Rinaldi Disseminated phaeohyphomycosis: Review of an emerging mycosis Clin Infect Dis 34 2002 467 476
68. M Nucci, T Akiti, G Barreiros Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infection J Clin Microbiol 39 2001 514 518
69. WJ Steinbach, WA Schell, JL Miller, JR Perfect Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide J Clin Microbiol 41 2003 3981 3985
70. E Dannaoui, JF Meis, D Loebenberg, PE Verweij Activity of posaconazole in treatment of experimental disseminated zygomycosis Antimicrob Agents Chemother 47 2003 3647 3650
71. K Kobayashi, M Kami, N Murashige, Y Kishi, G Fujisaki, T Mitamura Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis Haematologica 89 2004 ECR42
72. S Vigouroux, O Morin, P Moreau Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required Clin Infect Dis 40 2005 e35 e37
73. I Oren Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia Clin Infect Dis 40 2005 770 771
74. DP Kontoyiannis, MS Lionakis, RE Lewis Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases J Infect Dis 191 2005 1350 1359
75. A Imhof, SA Balajee, DN Fredricks, JA Englund, KA Marr Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole Clin Infect Dis 39 2004 743 746
76. GT Siwek, KJ Dodgson, M de Magalhaes-Silverman Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis Clin Infect Dis 39 2004 584 587
77. FM Marty, LA Cosimi, LR Baden Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants N Engl J Med 350 2004 950 952
78. D Andreson, A Donaldson, L Choo Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka Lancet 365 2005 876 878
79. CA Kauffman Zygomycosis: reemergence of an old pathogen Clin Infect Dis 39 2004 588 590
80. Greenberg RN, Anstead G, Herbrecht R, et al. Posaconazole (POS) experience in the treatment of zygomycosis (abstract M-1757). 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 14-17, 2003; Chicago, IL: 476.
81. R Herbrecht, V Letscher-Bru, RA Bowden Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion Eur J Clin Microbiol Infect D 20 2001 460 466
82. CE Gonzalez, DR Couriel, TJ Walsh Disseminated zygomycosis in a neutropenic patient: Successful treatment with amphotericin B lipid complex and granuloyte colony-stimulating factor Clin Infect Dis 24 1997 192 196
83. TJ Walsh, JW Hiemenz, NL Seibel Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases Clin Infect Dis 26 1998 1383 1396
84. TJ Walsh, JL Goodman, P Pappas Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study Antimicrob Agents Chemother 45 2001 3487 3496
85. R Herbrecht, DW Denning, TF Patterson Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
86. S Ascioglu, JH Rex, B de Pauw Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus Clin Infect Dis 34 2002 7 14
87. D Caillot, JF Couaillier, A Bernard Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia J Clin Oncol 19 2001 253 259
88. Greene RE, Schlamm HT, Stark P. et al. Radiological findings in acute invasive pulmonary aspergillosis: utility and reliability of halo sign and air-crescent sign for diagnosis and treatment of IPA in high-risk patients (abstract O397). Program of the 13th European Congress of Clinical Microbiology and Infectious Diseases; May, 2003; Glasgow.
89. US Food and Drug Administration FDA clears rapid test for Aspergillus infection 2003 US Food and Drug Administration
90. J Maertens, J Verhaegen, K Lagrou, J Van Eldere, M Boogaerts Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation Blood 97 2001 1604 1610
91. A Sulahian, M Tabouret, P Ribaud Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of aspergillosis Eur J Clin Microbiol Infect D 15 1996 139 145
92. CMA Swanink, JFGM Meis, AJMM Rijs, JP Donnelly, PE Verweij Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan J Clin Microbiol 35 1997 257 260
93. R Herbrecht, V Letscher-Bru, C Oprea Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients J Clin Oncol 20 2002 1898 1906
94. C Pinel, H Fricker-Hidalgo, B Lebeau Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis J Clin Microbiol 41 2003 2184 2186
95. MA Mennink-Kersten, JP Donnelly, PE Verweij Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis Lancet Infect Dis 4 2004 349 357
96. KA Marr, SA Balajee, L McLaughlin, M Tabouret, C Bentsen, TJ Walsh Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance J Infect Dis 190 2004 641 649
97. J Maertens, K Theunissen, E Verbeken Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients Br J Haematol 126 2004 852 860
98. MA Mennink-Kersten, RR Klont, A Warris, HJ Op den Camp, PE Verweij Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection Lancet 363 2004 325 327
99. A Sulahian, S Touratier, P Ribaud False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam N Engl J Med 349 2003 2366 2367
100. C Viscoli, M Machetti, P Cappellano False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam Clin Infect Dis 38 2004 913 916
101. TJ Walsh, S Shoham, R Petraitiene Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction J Clin Microbiol 42 2004 4744 4748
102. O Penack, S Schwartz, E Thiel, I Wolfgang Blau Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam Clin Infect Dis 39 2004 1401 1402
103. D Mattei, D Rapezzi, N Mordini False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment J Clin Microbiol 42 2004 5362 5363
104. Mennink-Kersten MAS, Klont RR, Ruegebrink D, Op den Camp H, Verweij PE. Amoxicillin-clavulanic acid (AMC) and piperacillin-tazobactam (PTZ) contain high molecular weight cross reacting aspergillus antigen (abstract M-1684a). Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct 30-Nov 2, 2004; Washington, DC.
105. C Viscoli, M Machetti, P Gazzola Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis J Clin Microbiol 40 2002 1496 1499
106. MJ Becker, EJ Lugtenburg, JJ Cornelissen, C Van Der Schee, HC Hoogsteden, S De Marie Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis Br J Haematol 121 2003 448 457
107. RR Klont, MA Mennink-Kersten, PE Verweij Utility of Aspergillus antigen detection in specimens other than serum specimens Clin Infect Dis 39 2004 1467 1474
108. T Miyazaki, S Kohno, K Mitsutake Plasma (1→3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis J Clin Microbiol 33 1995 3115 3118
109. Z Odabasi, G Mattiuzzi, E Estey Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome Clin Infect Dis 39 2004 199 205
110. C Costa, JM Costa, C Desterke, F Botterel, C Cordonnier, S Bretagne Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis J Clin Microbiol 40 2002 2224 2227
111. C Costa, D Vidaud, M Olivi, E Bart-Delabesse, M Vidaud, S Bretagne Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum J Microbiol Meth 44 2001 263 269
112. J Loeffler, H Hebart, U Brauchle, U Schumacher, H Einsele Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR J Clin Microbiol 38 2000 3830 3833
113. AS Pham, JJ Tarrand, GS May, MS Lee, DP Kontoyiannis, XY Han Diagnosis of invasive mold infection by real-time quantitative PCR Am J Clin Pathol 119 2003 38 44
114. J Loeffler, H Hebart, P Cox, N Flues, U Schumacher, H Einsele Nucleic acid sequence-based amplification of Aspergillus RNA in blood samples J Clin Microbiol 39 2001 1626 1629
115. B Musher, D Fredricks, W Leisenring, SA Balajee, C Smith, KA Marr Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid J Clin Microbiol 42 2004 5517 5522
116. D Buchheidt, M Hummel, D Schleiermacher Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients Br J Haematol 125 2004 196 202
117. M Kawazu, Y Kanda, Y Nannya Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders J Clin Microbiol 42 2004 2733 2741
118. PE Verweij, RR Klont, JP Donnelly Validating PCR for detecting invasive aspergillosis Br J Haematol 127 2004 235 236
119. Mennink-Kersten MASH, Ruegebrink D, Klont RR, Melchers WJG, Verweij PE. Fungal DNA is not released by Aspergillus fumigatus in an in vitro kinetic model (abstract M-1677). In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 30 Oct-2 Nov, 2004; Washington, DC.
120. MJ Becker, S de Marie, D Willemse, HA Verbrugh, IA Bakker-Woudenberg Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model J Clin Microbiol 38 2000 1434 1438
121. C Pazos, J Ponton, A Del Palacio Contribution of (1→3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan J Clin Microbiol 43 2005 299 305
122. J Wheat Histoplasma capsulatum antigen detection: Comparison of the performance characteristics of a new inhibition immunoassay to those of an established antibody sandwich immunoassay J Clin Microbiol 37 1999 2387
123. TJ Walsh, JW Hathorn, JD Sobel Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis N Engl J Med 324 1991 1026 1031
124. PE Verweij, D Poulain, T Obayashi, TF Patterson, DW Denning, J Ponton Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections Med Mycol 36 1998 146 155
125. B Sendid, JL Poirot, M Tabouret Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species J Med Microbiol 51 2002 433 442
126. DA Stevens, VL Kan, MA Judson Practice guidelines for diseases caused by Aspergillus Clin Infect Dis 30 2000 696 709
127. DW Bates, L Su, DT Yu Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 32 2001 686 693
128. JR Wingard, P Kubilis, L Lee Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis Clin Infect Dis 29 1999 1402 1407
129. L Ostrosky-Zeichner, KA Marr, JH Rex, SH Cohen Amphotericin B: time for a new "gold standard" Clin Infect Dis 37 2003 415 425
130. A Imhof, RB Walter, A Schaffner Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study Clin Infect Dis 36 2003 943 951
131. JP Barrett, KA Vardulaki, C Conlon A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations Clin Ther 25 2003 1295 1320
132. R Bowden, P Chandrasekar, MH White A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients Clin Infect Dis 35 2002 359 366
133. JR Wingard, MH White, E Anaissie, J Raffalli, J Goodman, A Arrieta A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia Clin Infect Dis 31 2000 1155 1163
134. ACAP Leenders, S Daenen, RLH Jansen Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections Br J Haematol 103 1998 205 212
135. JH Rex, PG Pappas, AW Karchmer A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 2003 1221 1228
136. D Caillot, H Bassaris, A McGeer Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS Clin Infect Dis 33 2001 E83 E90
137. KA Marr, F Crippa, W Leisenring Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood 103 2004 1527 1533
138. DW Denning, P Ribaud, N Milpied Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 2002 563 571
139. R Ally, D Schurmann, W Kreisel A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients Clin Infect Dis 33 2001 1447 1454
140. R Petraitiene, V Petraitis, AH Groll Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia Antimicrob Agents Chemother 45 2001 857 869
141. Hachem RY, Raad II, Afif CM, et al. An open, noncomparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: 2000.
142. WR Kirkpatrick, S Perea, BJ Coco, TF Patterson Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis J Antimicrob Chemother 49 2002 353 357
143. V Petraitis, R Petraitiene, AA Sarafandi Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin J Infect Dis 187 2003 1834 1843
144. WR Kirkpatrick, S Perea, BJ Coco, TF Patterson Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis Antimicrob Agents Chemother 46 2002 2564 2568
145. J Maertens, I Raad, G Petrikkos Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 2004 1563 1571
146. DW Denning Echinocandin antifungal drugs Lancet 362 2003 1142 1151
147. DS Krause, J Reinhardt, JA Vazquez Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia Antimicrob Agents Chemother 48 2004 2021 2024
148. PK Linden, K Coley, P Fontes, JJ Fung, S Kusne Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B Clin Infect Dis 37 2003 17 25
149. SM Palmer, RH Drew, JD Whitehouse Safety of aerosolized amphotericin B lipid complex in lung transplant recipients Transplantation 72 2001 545 548
150. AY Peleg, ML Woods Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients J Antimicrob Chemother 54 2004 803 808
151. D Andes, T Stamsted, R Conklin Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model Antimicrob Agents Chemother 45 2001 922 926
152. V Petraitis, R Petraitiene, AH Groll Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis Antimicrob Agents Chemother 45 2001 471 479
153. R Petraitiene, V Petraitis, AH Groll Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia Antimicrob Agents Chemother 46 2002 12 23
154. V Petraitis, R Petraitiene, AH Groll Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits Antimicrob Agents Chemother 46 2002 1857 1869
155. JC Bowman, PS Hicks, MB Kurtz The antifungal echinocandin caspofungin ccetate kills growing cells of Aspergillus fumigatus in vitro Antimicrob Agents Chemother 46 2002 3001 3012
156. KA Marr, R Hachem, G Papanicolaou Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A Transpl Infect Dis 6 2004 110 116
157. JA van Burik, V Ratanatharathorn, DE Stepan Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 2004 1407 1416
158. M Boogaerts, DJ Winston, EJ Bow Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial Ann Intern Med 135 2001 412 422
159. DJ Winston, RT Maziarz, PH Chandrasekar Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial Ann Intern Med 138 2003 705 713
160. WJ Steinbach, DA Stevens Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis Clin Infect Dis 37 suppl 3 2003 S157 S187
161. Troke PF, Schwartz S, Ruhnke M, et al. Voriconazole (VRC) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis (M-1755). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: Sept 14-17, 2003: 476.
162. L Ostrosky-Zeichner, AM Oude Lashof, BJ Kullberg, JH Rex Voriconazole salvage treatment of invasive candidiasis Eur J Clin Microbiol Infect Dis 22 2003 651 655
163. Kullberg BJ, Pappas P, Ruhnke M, et al. Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment of candidaemia in non-neutropenic patients (abstract O245). 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague: 1-4 May, 2004.
164. WR Kirkpatrick, RK McAtee, AW Fothergill, D Loebenberg, MG Rinaldi, TF Patterson Efficacy of posaconazole in a rabbit model of invasive aspergillosis Antimicrob Agents Chemother 44 2000 780 782
165. MS Saag, RJ Graybill, RA Larsen Practice guidelines for the management of cryptococcal disease Clin Infect Dis 30 2000 710 718
166. Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or combination therapy with voriconazole and liposomal amphotericin B in a guinea pig model of Aspergillosis. Program and Abstracts of Trends in Invasive Fungal Infections 7; Sept 28-Oct 1; Amsterdam; 2003.
167. DP Kontoyiannis, R Hachem, RE Lewis Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer 98 2003 292 299
168. TB Aliff, PG Maslak, JG Jurcic Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin Cancer 97 2003 1025 1032
169. Kohno S, Maesaki S, Iwakawa J, et al. Synergistis effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, CA, USA.
170. SP Bachmann, K VandeWalle, G Ramage In vitro activity of caspofungin against Candida albicans biofilms Antimicrob Agents Chemother 46 2002 3591 3596
171. Douglas CM, Abruzzo G, Bowman JC, et al. Caspofungin alone or in combination with itraconazole reduces fungal burden in a neutropenic guinea pig model of disseminated aspergillosis. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, CA, USA: M-1819.
172. MA Rubin, KC Carroll, BC Cahill Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans Clin Infect Dis 34 2002 1160 1161
173. KA Marr, M Boeckh, RA Carter, HW Kim, L Corey Combination antifungal therapy for invasive aspergillosis Clin Infect Dis 39 2004 797 802
174. A Schaffner, PG Frick The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis J Infect Dis 151 1985 902 910
175. Boucher HW, Herbrecht R, Bennett JW, et al. The strategy of following voriconazole (VRC) vs amphotericin B (AMB) with other licensed antifungal therapy (OLAT) for primary therapy of invasive aspergillosis (IA) (abstract M-964). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003: 446.
176. D George, D Kordick, P Miniter, TF Patterson, VT Andriole Combination therapy in experimental invasive aspergillosis J Infect Dis 168 1993 692 698
177. AE Brouwer, A Rajanuwong, W Chierakul Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial Lancet 363 2004 1764 1767
178. SP Bachmann, G Ramage, K VandeWalle, TF Patterson, BL Wickes, JL Lopez-Ribot Antifungal combinations against Candida albicans biofilms in vitro Antimicrob Agents Chemother 47 2003 3657 3659
179. DW Denning, LH Hanson, AM Perlman, DA Stevens In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents Diagn Microbiol Infect Dis 15 1992 21 34
180. DW Denning, DA Stevens Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases Rev Infect Dis 12 1990 1147 1201
181. WJ Steinbach, DA Stevens, DW Denning Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001 Clin Infect Dis 37 suppl 3 2003 S188 S224
182. Nakajima M, Tamada S, Yoshida K, et al. Pathological findings in a murine pulmonary aspergillosis model: Treatment with FK463, amphotericin B, and a combination of FK463 and amphotericin B. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, CA, USA.
183. C Viscoli Combination therapy for invasive aspergillosis Clin Infect Dis 39 2004 803 805